This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Schafer AI . Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214–4222.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH . JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007; 21: 1097–1099.
Campbell PJ, Scott LM, Buck G, Wheatley K, Easy CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
Tefferi A, Lasho T, Schwager SM, Strand JS, Elliot M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631–635.
Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R . The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249–259.
Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T . Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.
Vannucchi AM, Antonioli E, Guglielmelli P, Rambalde A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, E-pub ahead of print, 22 March.
Acknowledgements
We thank Professor J Patrick Barron of the International Medical Communication Center of Tokyo Medical University for his review of this manuscript and Mr K Hori and T Makino, NovusGene, Tokyo, for their technical assistance. This work was supported in part by the ‘High-Tech Research Center’ Project from the Ministry of Education, Culture, Sports and Technology (MEXT) and by the ‘University-Industry Joint Research Project’ from MEXT.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Ohyashiki, K., Akahane, D., Gotoh, A. et al. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2V617F mutational status. Leukemia 21, 2544–2545 (2007). https://doi.org/10.1038/sj.leu.2404829
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404829